For instance, while PD-1 inhibitors demonstrate similar irAE rates in melanoma and lung cancer, melanoma patients exhibit a higher prevalence of dermatologic (e.g., vitiligo) or gastrointestinal irAEs, whereas lung cancer and renal cell carcinoma patients are more prone to pneumonitis. This evidence concerns the gene PDCD1 and pneumonitis.